MedTrace Logo

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

NCT05748587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2024-06-25

No results posted yet for this study

Summary

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:

* Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?
* Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Conditions

  • Brain Ischemia

Interventions

DIAGNOSTIC_TEST

Serum Iron

Serum iron levels in study groups

DIAGNOSTIC_TEST

RBCs Alpha-synuclein

α-syn levels in RBCs

DIAGNOSTIC_TEST

Serum Soluble lymphocyte activation gene

sLAG-3 in the serum of study groups

RADIATION

Brain computed tomography

Brain CT of patients after admission

DIAGNOSTIC_TEST

Brain Iron

Iron in brain homogenate of rats

DIAGNOSTIC_TEST

Brain Alpha-synuclein

α-syn expression in rat's brain

DIAGNOSTIC_TEST

Brain lymphocyte activation gene

LAG-3 expression in rat's brain

DRUG

Deferoxamine

intramuscular deferoxamine (200 mg/kg) injection to rats

Sponsors & Collaborators

  • Aswan University Hospital

    lead OTHER

Principal Investigators

  • Asmaa Abdelmageed Muhammed · Aswan University Hospital

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2024-03-01
Completion
2024-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05748587 on ClinicalTrials.gov